Articles On Zelda Therapeutics (ASX:ZLD)
Title | Source | Codes | Date |
---|---|---|---|
ASX Health Stocks: Nyrada gets closer to European patent, and HOPE for Zelira’s autism tincture
Nyrada’s European patent submission gets a patent number Zelira’s positive study results on its autism tincture, HOPE Beamtree gives beaming trading update Cardiovascular and neurological diseases fighter, Nyrada (ASX: NYR), says the Eur... |
Stockhead | ZLD | 1 year ago |
Market Highlights and 5 ASX Small Caps to watch on Tuesday
ASX to open higher as Wall Street returns a mixed bag Oil prices are higher by 3% El Salvador to host a Bitcoin summit with 44 other countries/institutions Aussie shares are set to open higher this morning, despite a mixed bag of results... |
Stockhead | ZLD | 1 year ago |
Weed Week: US seed bank launches 4/20 day NFT collection and Washington has a cannabis tax holiday
US Seed Connect launched Cannabis Crypto Seed Headz NFT Washington launches week-long cannabis tax holiday Medlab clinical makes moves in the Northern Hemisphere with manufacturing deal Wednesday was 4/20 day – while it’s more of an unoff... |
Stockhead | ZLD | 1 year ago |
Zelira Therapeutics executes acquisition of Health House
Zelira Therapeutics (ASX:ZLD) has announced it has executed a binding scheme implementation deed under which it proposes to acquire 100 per cent of Health House. |
BiotechDispatch | ZLD | 1 year ago |
Weed Week: New York hemp farmers get green light for cannabis crops
Hemp farmers in New York have been given the go ahead to plant cannabis for the 2022 season. The legislation allows conditionally licensed cannabis farmers to grow weed, but they must meet certain requirements, including safe, sustainable a... |
Stockhead | ZLD | 2 years ago |
ASX Health Stocks: Here’s a highlight from today’s half-year result announcements
At the time of writing, the ASX 200 Health Index (XHJ) is down by 1.10%, while the benchmark ASX 200 has fallen by 2.15%. It’s all about earnings today for ASX health stocks. Here’s a highlight of where they stand in the first half. Round... |
Stockhead | ZLD | 2 years ago |
Zelira Therapeutics (ASX:ZLD) set to acquire Health House International
Zelira Therapeutics (ZLD) is set to take over Health House International to expand the market reach of its medicinal cannabis products Under the scheme, Zelira will issue shares to Health House parties at 19.45 per cent interest in the exp... |
themarketherald.com.au | ZLD | 2 years ago |
Board changes for Zelira Therapeutics
Zelira Therapeutics (ASX:ZLD), a company focused on the development of clinically validated cannabis medicines, has appointed Tim Slate as a non-executive director. |
BiotechDispatch | ZLD | 2 years ago |
ASX Health Stocks: Immuron up 29pc on $6.2m travellers’ diarrhoea clinical study for US military
Immuron nabs $6.2m clinical research deal for US Military strength Travelan dose ECS Botanics reports record revenue of $1.5m expected for Q2 FY22 Compumedics secures first major magnetoencephalography (MEG) sale in China Immuron (ASX:IMC... |
Stockhead | ZLD | 2 years ago |
Zelira Therapeutics (ASX:ZLD) receives $1.29 million cash R&D incentive
Zelira Therapeutics (ZLD) has received a $1.29 million cash refund under the Federal Government’s research and development tax incentive scheme. The cash was part of a program under which companies receive refunds for eligible expenditure... |
themarketherald.com.au | ZLD | 2 years ago |
Zelira (ASX:ZLD) paid US$250,000 for cannabinoid technology
Zelira Therapeutics (ZLD) has received US$250,000 (A$348,000) for its technology which enables the enhanced dissolution of cannabinoids The company expects to receive the full US$1 million upfront, non-refundable, non-contingent licence pa... |
themarketherald.com.au | ZLD | 2 years ago |
Zelira Therapeutics (ASX:ZLD) expands into New Zealand
Zelira Therapeutics (ZLD) expands into the New Zealand cannabinoid-based medicines market via a five year exclusive distribution agreement with NUBU Pharmaceuticals The deal allows Zelira to market its Zenivol and Hope 1 products in New Ze... |
themarketherald.com.au | ZLD | 2 years ago |
ASX Health Stocks: CSL drags Healthcare index down 5pc on a mammoth $6.3bn cap raise
The ASX 200 Health Index (XHJ) has dropped by almost 5% at the time of writing, compared to the broader index which is down by 0.20%. Healthcare giant and blood specialist, CSL (ASX:CSL), which makes up a large part of the ASX Healthcare in... |
Stockhead | ZLD | 2 years ago |
Market Highlights and 5 ASX Small Caps to watch on Thursday
Wall Street rallies on Fed decision US stocks rallied strongly overnight, as investors digested the central bank’s decision to speed up its tapering program and hike rates next year. Fed Reserve governor Jerome Powell said the bank will red... |
Stockhead | ZLD | 2 years ago |
Zelira Therapeutics confirms ethics approval for chronic pain study
Zelira Therapeutics (ASX:ZLD) has announced ethics approval has been granted for the Phase 2a clinical trial of its cannabinoid formulation, ZTL-106, in treating patients with chronic pain. |
BiotechDispatch | ZLD | 2 years ago |
Zelira Therapeutics (ASX:ZLD) granted ethics approval for chronic pain trial
Zelira Therapeutics (ZLD) receives ethics approval for its Phase 2a clinical trial for chronic pain As part of its licensing and project management with Levin Health, the study will evaluate the efficacy of Zelira’s cannabinoid formulation... |
themarketherald.com.au | ZLD | 2 years ago |
Zelira Therapeutics (ASX:ZLD) signs US$1m licensing deal
Zelira Therapeutics (ZLD) signs a licensing deal for its Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology DRCN Holding will pay a US$1 million (A$1.35 million) licensing fee for the tech and has three years to develop... |
themarketherald.com.au | ZLD | 2 years ago |
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Fresh record highs on Wall Street ahead of Fed statement US stocks continued their strong recent run overnight, and finished at fresh record levels for the third day in a row. All three benchmarks indexes rose – the Dow Jones rose by 0.39%,... |
Stockhead | ZLD | 2 years ago |
Closing Bell: ASX shrugs it off with another day of gains as investors clamour for more IPOs
As the world emerges from the pandemic, markets are now contending with an energy crisis, a global shipping glut and the prospect of central banks starting to raise interest rates. But so far this week, investors are shrugging it all off as... |
Stockhead | ZLD | 2 years ago |
Zelira Therapeutics (ASX:ZLD) recieves funding from Quincy Street
Zelira Therapeutics (ZLD) raises US$5 million (around A$6.69) from US family office fund, Quincy Street Capital Quincy Street has now become a substantial shareholder in Zelira with a 6.3 per cent stake Funds from the raise will be used to... |
themarketherald.com.au | ZLD | 2 years ago |
Closing Bell: ASX fails to maintain gains, despite tech gaining 1.7pc
Just like yesterday the ASX rallied for most of the day but retreated in the afternoon and today closed in the red. The ASX 200 was down 0.08% at 7,375 points. Another difference from yesterday was tech was the best sector gaining 1.7% whil... |
Stockhead | ZLD | 2 years ago |
Zelira Therapeutics (ASX:ZLD) enters trading halt ahead of capital raise
Zelira Therapeutics (ZLD) calls a two-day trading halt as it gears up to raise some fresh funds The company is yet to announce how much it plans to raise or for what it will use the funding boost Taking a look at Zelira’s latest financial... |
themarketherald.com.au | ZLD | 2 years ago |
Weed Week: Amazon scraps marijuana drug tests and Victorian council considers cannabis crops
Retail giant Amazon has rejigged its cannabis policy, allowing employees who were previously fired for testing positive for marijuana to reapply for jobs. The company has now excluded marijuana from its comprehensive pre-employment drug scr... |
Stockhead | ZLD | 2 years ago |
Market Highlights and 5 ASX Small Caps to watch on Thursday
Wall Street higher as US Fed firms up November tapering US stock markets were higher overnight, as US Fed Chairman Jerome Powell signalled the bank would start tapering its asset purchases starting in November, which would last until the mi... |
Stockhead | ZLD | 2 years ago |
Market Highlights and 5 ASX Small Caps to watch on Monday
Wall Street slips as iron ore falls further All three US stock market indexes fell on Friday, ahead of the US Fed rates decision this Wednesday (US time). The Dow Jones fell by 0.48%, S&P500 by 0.91%, and the tech heavy Nasdaq also fell... |
Stockhead | ZLD | 2 years ago |
Hidden Gems Webinar Recap – ZLD, WTL, AGN, CLA
ShareCafeHidden Gems Webinar Recap – ZLD, WTL, AGN, CLA Catch up on the full webinar with presentations from Zelira Therapeutics (ASX: ZLD), Argenica Therapeutics (ASX:AGN), WT Financial Group (ASX: WTL) & Celsius Resources Limited (... |
ShareCafe | ZLD | 2 years ago |
Market highlights and 5 ASX small caps to watch on Monday
Wall Street at fresh record highs All three key US benchmarks rose and reached fresh record highs on Friday, ahead of kick-off in earnings season. The Dow Jones was up by 1.30%, S&P 500 by 1.13%, and tech heavy Nasdaq by 0.98%. Bank sto... |
Stockhead | ZLD | 2 years ago |
Blazing it? How the top ASX cannabis shares performed in FY21
The 2021 financial year was overall a very good one for ASX shares. The S&P/ASX 200 Index (ASX: XJO) managed to put on a performance of 24% for the 12 months to 30 June 2021. That makes FY2021 one of the best financial years ever for t... |
Motley Fool | ZLD | 2 years ago |
Cannabis stocks celebrate Pershing ownership change
Cannabis stocks have welcomed the change in ownership of Pershing Australia from Bank of New York Mellon (BNYM) to Finclear Pty Ltd which – effective immediately – will allow the trading of cannabis securities on the ASX. In late 2019, BNYM... |
Stockhead | ZLD | 2 years ago |
Weed Week: Connecticut and Mexico on board cannabis bandwagon, as Rinehart enters the industry
Connecticut has become the latest US state to legalise recreational use of marijuana. The state’s governor has just signed a bill to allow people aged 21 and older to possess and consume marijuana, making it the 19th US state to do so. Here... |
Stockhead | ZLD | 2 years ago |
Weed Week: Amazon all-in on marijuana; free joints for jabs and Creso Pharma dual-listed in US
The US cannabis sector received a big lift after Amazon announced that job applicants at its offices and warehouses will no longer be drug-tested for marijuana use. Delivery drivers, however, will still be tested. The company also said it w... |
Stockhead | ZLD | 2 years ago |
Last Orders: ASX gains nearly 1 per cent back from the long weekend
The ASX 200 just closed 0.92 per cent up at 7,380 points — a new record high. The ASX Emerging Companies Index however fell 1.66 per cent, closing at 2,180. The best sector on the ASX was health which gained over 2 per cent while consumer... |
Stockhead | ZLD | 2 years ago |
Market highlights and 5 ASX small caps to watch on Tuesday
Wall Street mixed ahead as Nasdaq hits record highs Major indices in the US were mixed on Monday, with tech stocks leading the way, ahead of Thursday’s US Fed key policy meeting. The Dow Jones fell by 0.25%, S&P 500 rose by 0.18%, and t... |
Stockhead | ZLD | 2 years ago |
Building an export industry for cannabis medicines
The medicinal cannabis industry is gaining significant momentum, however, still remains in the early stages of growth. Zelira Therapeutics recently reported record quarterly cash receipts for the third quarter, up 249 per cent on H1 FY21. F... |
Montgomery | ZLD | 2 years ago |
Five ASX penny stocks making positive moves today
Summary Hillgrove Resources’ share price has skyrocketed 64.8% today and is currently trading at AU$0.089. Today, Veris’ share has given a breakout from a consolidation phase on the chart. The Red Sky Energy share price is also runnin... |
Kalkine Media | ZLD | 2 years ago |
Why are ASX healthcare shares Rhythm Biosciences and Zelira on the rise today?
Summary Diagnostics company Rhythm Biosciences has confirmed that LRF enhancements have shown to improve ColoSTAT® results. Cannabis medicines developer Zelira Therapeutics has entered into a partnership with Alternative Solutions for... |
Kalkine Media | ZLD | 2 years ago |
Why the Zelira (ASX:ZLD) share price is storming 7% higher
The Zelira Therapeutics Ltd (ASX: ZLD) share price is firmly in the green today following a positive update for its HOPE products. At the time of writing, the cannabis company’s shares are swapping hands for 5.7 cents, up 7.55%. What did Z... |
Motley Fool | ZLD | 2 years ago |
Market highlights and 5 ASX small caps to watch on Thursday
Dow Jones at record level, as US tech stocks sell off again The Dow Jones index has reached its all-time high, rising by 0.29% to finish at a record 34,230. However, tech stocks sold off again, with the likes of Amazon and Facebook falling... |
Stockhead | ZLD | 2 years ago |
How did Splitit Payments (ASX:SPT) fare in Q1 FY21?
Summary ASX-listed Splitit Payments Limited announced strong growth in Merchant Sales Volume (MSV) and revenue in Q1 FY2021. The Company’s brand awareness increased during the quarter, evident by the 70K increase in new shoppers. The... |
Kalkine Media | ZLD | 2 years ago |
Zelira (ASX:ZLD) share price falls despite strong trading update
The Zelira Therapeutics Ltd (ASX: ZLD) share price is lower during mid-afternoon trade despite announcing a positive trading update. At the time of writing, the cannabis company’s shares are fetching for 5.9 cents, down 1.67%. Q3 FY21 quar... |
Motley Fool | ZLD | 2 years ago |
Zelira announces record revenue in the march quarter
Zelira Therapeutics (ASX:ZLD) says it generated record quarterly product sales and licensing revenues of $225,000 for the March 2021 quarter, up 249 per cent from the previous six months. |
BiotechDispatch | ZLD | 2 years ago |
Market highlights and 5 ASX small caps to watch on Thursday
Wall Street mixed, even as banks’ earnings beat estimates US investors took the strong banks’ earnings in stride, with the major US indices petering out to a mixed finish. Major banks Goldman Sachs, JP Morgan and Wells Fargo unveiled quarte... |
Stockhead | ZLD | 2 years ago |
What will Elite Cannabinoids mean for ASX cannabis shares?
In what may be a catalyst for ASX cannabis shares, a private company today gained approval to grow medicinal cannabis in Western Australia. As reported by the ABC, the private medicinal cannabis company Elite Cannabinoids has received appr... |
Motley Fool | ZLD | 3 years ago |
The sector that’ll grow 480% this year, expert says
There is a sector in Australia that’s about to grow its revenue by 478% in the current financial year, according to one analyst. Consumer research firm IBISWorld revealed Tuesday that the medical cannabis manufacturing industry is currentl... |
Motley Fool | ZLD | 3 years ago |
5 top ASX cannabis shares in 2020
Investors in ASX cannabis shares have had a bumpy ride in 2020. Share prices were impacted by global oversupply issues in late 2019 then plunged in the March 2020 market downturn. But the Australian medical marijuana industry is building... |
Motley Fool | ZLD | 3 years ago |
Zelira Therapeutics Share Price Soars on Distribution Agreement
The share price of medical cannabis company Zelira Therapeutics Ltd (ASX:ZLD) has rocketed today thanks to a distribution agreement in the Washington DC area, US. At time of writing the ZLD share price is up 36.36% or 3.6 cents to trade at... |
MoneyMorning | ZLD | 3 years ago |
Here’s why the Zelira (ASX:ZLD) share price just rocketed to a new high
The Zelira Therapeutics Ltd (ASX: ZLD) share price is breaking new records today. This comes after the company announced a new licencing agreement with Alternative Solutions LLC. Alternative Solutions is a licenced grower, manufacturer and... |
Motley Fool | ZLD | 3 years ago |
Zelira shares soar after expanding US medical pot distribution
Shares in Zelira Therapeutics (ASX:ZLD) have risen more than 30 per cent to a nearly two-year high in early trade ... Read More The post Zelira shares soar after expanding US medical pot distribution appeared first on Stockhead. |
Stockhead | ZLD | 3 years ago |
Zelira Therapeutics’ (ASX:ZLD) September Quarter celebrates key milestones
Summary During September quarter, Zelira Therapeutics achieved significant milestones marking its successful transition to the ‘Launch, Learn and Develop’ model. Key developments include the launch of Zenivol™ in Australia and HOPE™ in... |
Kalkine Media | ZLD | 3 years ago |
Zelira Therapeutics (ASX:ZLD) sinks its teeth into US Oral Care Market with CBD toothpaste
Summary Zelira Therapeutics forays into the US oral care market by launching CBD toothpaste in partnership with US-based SprinJene®. The new CBD toothpaste will be Zelira’s first Over-the-Counter formulation. Further, the discussions... |
Kalkine Media | ZLD | 3 years ago |